Drug-resistant tuberculosis(DR-TB)continues to be a public health concern.In 2019,nearly half a million patients had rifampicin-resistant tuberculosis(RR-TB),with 78%of those having multidrug-resistant TB(MDR-TB).Indi...Drug-resistant tuberculosis(DR-TB)continues to be a public health concern.In 2019,nearly half a million patients had rifampicin-resistant tuberculosis(RR-TB),with 78%of those having multidrug-resistant TB(MDR-TB).India(27%),China(14%),and the Russian Federation(8%)are the three countries with the highest share of the global burden.展开更多
文摘Drug-resistant tuberculosis(DR-TB)continues to be a public health concern.In 2019,nearly half a million patients had rifampicin-resistant tuberculosis(RR-TB),with 78%of those having multidrug-resistant TB(MDR-TB).India(27%),China(14%),and the Russian Federation(8%)are the three countries with the highest share of the global burden.
